Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine Ophthalmic Solution 0.1% for Corneal Endothelial Health in Dry Eye Disease
NCT06329661Phase 4Completed
- Sponsor
- Novaliq GmbH
- Start
- Apr 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
A Phase 4 trial of cyclosporine 2% ophthalmic solution in dry eye disease (DED), sponsored by Novaliq GmbH. Started Apr 2024; status: completed.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06329661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06329661.